Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

NCT00066690 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

3066

Enrollment

NETWORK

Sponsor class

Conditions

Estrogen Receptor Positive Breast Cancer
Progesterone Receptor Positive Tumor
Recurrent Breast Carcinoma
Stage IA Breast Cancer
Stage IB Breast Cancer
Stage IIA Breast Cancer
Stage IIB Breast Cancer
Stage IIIA Breast Cancer

Interventions

DRUG: Exemestane
OTHER: Laboratory Biomarker Analysis
PROCEDURE: Oophorectomy
OTHER: Quality-of-Life Assessment
RADIATION: Radiation Therapy
DRUG: Tamoxifen
DRUG: Triptorelin

Sponsor

ETOP IBCSG Partners Foundation

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]